A Phase 1 interventional study of PM01183 + paclitaxel +/- bevacizumab in Breast Cancer, Ovarian Cancer and Gynecological Cancer, sponsored by PharmaMar. Completed at 3 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-04-10.
Sponsored by PharmaMar · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 373 studies testing paclitaxel in Breast Neoplasms — 40 open to participants now, 60 under way, 13 of them phase 3. Paclitaxel · Breast Neoplasms.
Among the 373 studies testing paclitaxel in Breast Neoplasms, this one is the 159th largest by enrollment of the 361 interventional ones that give a count, is one of 21 that started in 2013, is one of 38 in phase 1, and was the 233rd registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →40 of the 373 studies testing paclitaxel in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Zhejiang Cancer Hospital · Sites in China
Ages 18+
Liu Shu · Sites in China
Ages 18–70 · Women only
RenJi Hospital · Sites in China
Ages 18–70 · Women only
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Women only
Jazz Pharmaceuticals · Sites in United States, Germany, Italy and 1 more country
Ages 18+
By country, each count listing its studies:
Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
373 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 74 · Phase 2 249 · Phase 3 69 · Phase 4 10
First in 1994; this study’s year is marked. 21 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 69 is close to the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 60 across the 361 interventional studies. Of the 254 that completed or were terminated, 125 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 373 have an industry lead sponsor. The 10 most frequent:
PharmaMar is the lead sponsor of 50 studies on the registry; 5 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
PharmaMar has 3 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
16 of the studies testing paclitaxel in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05183126University of Michigan Rogel Cancer CenterPharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer | 2026-11 |
| NCT03125928Fox Chase Cancer CenterClinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer | 2026-12 |
| NCT07283692RenJi HospitalNeoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT) | 2026-12 |
| NCT07580833Health Hope PharmaA Study to Investigate the Effect of Food on the Bioavailability of Oral Paclitaxel Administered With Encequidar in Participants With Advanced Solid Tumors | 2026-12 |
| NCT05383196Antonio Giordano, MDOnvansertib + Paclitaxel In TNBC | 2026-12-15 |
Add all 16 to your calendar (.ics) → With an account.
Among the 373 studies testing paclitaxel in Breast Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Clinical trial of PM01183 in combination with paclitaxel, with or without bevacizumab, in patients with solid tumors
Clinical trial to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM01183 in combination with weekly paclitaxel, with or without bevacizumab. Once a recommended dose is defined for the PM01183 and weekly paclitaxel combination, the feasibility of adding bevacizumab to this combination will be explored in a selected cohort of patients to characterize the safety profile and feasibility of this combination, to obtain preliminary information on antitumor activity, to obtain preliminary information on quality of life (QoL), to characterize the pharmacokinetics (PK) of this combination and to detect major drug-drug PK interactions and PK(pharmacokinetic)/PD(pharmacodynamic) correlation and to conduct an exploratory pharmacogenomic(PGx) analysis in patients with selected advanced solid tumors.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with a histologically/ confirmed diagnosis of advanced and/or unresectable disease of any of the following tumors:
Exclusion Criteria:
:
Unstable angina, myocardial infarction, valvular heart disease, encephalopathy, ischemic attacks, hemorrhagic or ischemic cerebrovascular accident (CVA) or ongoing pulmonary embolism within last year, arrhythmia, hepatopathy, uncontrolled infection, hemoptysis or oxygen requiring dyspnea, known infection, bleeding risk, muscular problems, peripheral neuropathy, Symptomatic or progressive or .
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PM01183 + paclitaxel +/- bevacizumab
Drug: PM01183 + paclitaxel +/- bevacizumab
Drug pages: PM 01183 · Paclitaxel · Bevacizumab
PM01183: 1 mg and 4 mg vials. Powder for concentrate for solution for infusion paclitaxel: 6 mg/ml concentrate for solution for infusion bevacizumab: 25 mg/ml concentrate for solution for infusion Once a recommended dose is defined for the PM01183 and weekly paclitaxel combination, the feasibility of adding bevacizumab to this combination will be explored in a prospectively selected cohort of patients
Maximum Tolerated Dose (MTD)
The MTD will be the lowest level at which one third or more evaluable patients experience a DLT in Cycle 1. DLTs are defined as AEs or laboratory abnormalities related to the study drugs occurred during Cycle 1.
Time frame: The MTD was followed mainly during Cycle 1 through study completion, an average of 5 cycles for PM1183 in cohort A and 9.5 cycles in cohort B were observed (cycle duration: 3 weeks)
Recommended Dose (RD)
The RD will be the highest DL explored with less than one third of the patients experiencing a DLT during Cycle 1. DLTs are defined as AEs or laboratory abnormalities related to the study drugs occurred during Cycle 1.
Time frame: The RD was followed mainly during Cycle 1 through study completion, an average of 5 cycles for PM1183 in cohort A and 9.5 cycles in cohort B were observed (cycle duration: 3 weeks)
Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)
DLTs are defined as AEs or laboratory abnormalities related to the study drugs occurred during Cycle 1.
Time frame: DLT was followed mainly during Cycle 1 through study completion, an average of 5 cycles for PM1183 in cohort A and 9.5 cycles in cohort B were observed (cycle duration: 3 weeks)
Best Tumor Response
Best overall response:Best response recorded from the start of the study treatment until the end of treatment Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to\<10 mm Partial Response (PR):At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression) Stable Disease (SD):Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum diameters while on study Treatment failure (TF):symptomatic deterioration or death due to progression
Time frame: Through study completion, an average of 5 cycles for PM1183 in cohort A and 9.5 cycles in cohort B were observed (1 cycle =3 weeks)
Progression-free Survival
Progression-free survival (PFS) was defined as the time from the date of first infusion of study treatment to the date of progression or death (due to any cause). If progression or death had not occurred at the time of the analysis, the PFS was censored.
Time frame: Through study completion, an average of 5 cycles for PM1183 in cohort A and 9.5 cycles in cohort B were observed (1 cycle =3 weeks)
Duration of Response (DR)
Duration of response (DR) was defined as the time from the date when the response criteria (PR or CR, whichever was reached first) were fulfilled, to the first date when PD, recurrence or death was documented
Time frame: Through study completion, an average of 5 cycles for PM1183 in cohort A and 9.5 cycles in cohort B were observed (1 cycle =3 weeks)
Quality of Life (QoL)
Change from baseline to last cycle. European Organization for Research and Treatment of Cancer (EORTC) QLQ-C15-PAL scale scores. The EORTC QLQ-C15-PAL is an abbreviated 15-item version of the EORTC QLQ-C30 (version 3.0) developed for palliative care. Wilcoxon signed ranks test repeat-measure analyses of variance were used to measure the change value from baseline value. Data has to be analysed following the corresponding EORTC manual http://www.eortc.be/qol/files/SCManualQLQ-C15-PAL.pdf and the overall quality of life assessment is contained in 0 to 100 where a higher value represents a better state.
Time frame: Through study completion, an average of 5 cycles for PM1183 in cohort A and 9.5 cycles in cohort B were observed (1 cycle =3 weeks)
A total of 69 patients were enrolled at 3 investigational sites: 55 Group A (paclitaxel plus PM01183) and 14 Group B (paclitaxel+PM01183 and BEV). Patients participated in this trial between 15/Oct/2013 and 14/Jul/2016 (last FU). The first dose of the first cycle was given on 23/Oct/2013 and the last dose of the last cycle was given on 23/Jun/2016
| Milestone | Paclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD] | Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FD | Paclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kg |
|---|---|---|---|---|---|---|
| Started | 3 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 3 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Paclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD] | Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FD | Paclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kg |
|---|---|---|---|---|---|---|
| Started | 0 | 3 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Clinical progressive disease | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Paclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD] | Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FD | Paclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kg |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 6 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 6 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 3 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Global end of study | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Paclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD] | Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FD | Paclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kg |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 6 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 6 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 6 | 0 | 0 |
| Milestone | Paclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD] | Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FD | Paclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kg |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 37 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 37 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 30 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 3 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Global end of study | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 |
| Milestone | Paclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD] | Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FD | Paclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kg |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 14 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 14 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 0 | 8 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Never treated | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Global end of study | 0 | 0 | 0 | 0 | 0 | 1 |
The MTD will be the lowest level at which one third or more evaluable patients experience a DLT in Cycle 1. DLTs are defined as AEs or laboratory abnormalities related to the study drugs occurred during Cycle 1.
| mg/m2 / mg FD | Group A (Paclitaxel/PM01183) |
|---|---|
| Maximum Tolerated Dose (MTD) | NA |
The RD will be the highest DL explored with less than one third of the patients experiencing a DLT during Cycle 1. DLTs are defined as AEs or laboratory abnormalities related to the study drugs occurred during Cycle 1.
| mg/m2 / mg FD | Group A (Paclitaxel/PM01183) |
|---|---|
| Recommended Dose (RD) | NA |
DLTs are defined as AEs or laboratory abnormalities related to the study drugs occurred during Cycle 1.
| Participants | Paclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD] | Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FD | Paclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kg |
|---|---|---|---|---|---|---|
| Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) | 0 | 0 | 2 | 3 | 6 | 3 |
Best overall response:Best response recorded from the start of the study treatment until the end of treatment Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to\<10 mm Partial Response (PR):At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression) Stable Disease (SD):Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum diameters while on study Treatment failure (TF):symptomatic deterioration or death due to progression
| Participants | Paclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD] | Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FD | Paclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kg |
|---|---|---|---|---|---|---|
| CR | 0 | 0 | 0 | 0 | 1 | 1 |
| PR | 1 | 0 | 2 | 4 | 12 | 4 |
| SD ≥3 months | 1 | 2 | 1 | 1 | 6 | 4 |
| SD <3 months | 0 | 0 | 1 | 0 | 1 | 0 |
| PD | 1 | 1 | 2 | 1 | 12 | 0 |
| Early PD | 0 | 0 | 0 | 0 | 1 | 0 |
| TF | 0 | 0 | 0 | 0 | 0 | 1 |
Progression-free survival (PFS) was defined as the time from the date of first infusion of study treatment to the date of progression or death (due to any cause). If progression or death had not occurred at the time of the analysis, the PFS was censored.
| months | Paclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD] | Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FD | Paclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kg |
|---|---|---|---|---|---|---|
| Progression-free Survival | 3.5 (1.7 to 5.6) | 3.1 (1.9 to 7.4) | 3.1 (1.0 to NA) | 5.4 (1.7 to 8.8) | 3.9 (1.9 to 6.0) | 6.7 (2.4 to 9.3) |
Duration of response (DR) was defined as the time from the date when the response criteria (PR or CR, whichever was reached first) were fulfilled, to the first date when PD, recurrence or death was documented
| months | Paclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD] | Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FD | Paclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kg |
|---|---|---|---|---|---|---|
| Duration of Response (DR) | 1.6 (NA to NA) | — | NA (2.0 to NA) | 2.2 (0.9 to 4.7) | 4.1 (2.1 to 8.3) | 4.6 (1.4 to NA) |
Change from baseline to last cycle. European Organization for Research and Treatment of Cancer (EORTC) QLQ-C15-PAL scale scores. The EORTC QLQ-C15-PAL is an abbreviated 15-item version of the EORTC QLQ-C30 (version 3.0) developed for palliative care. Wilcoxon signed ranks test repeat-measure analyses of variance were used to measure the change value from baseline value. Data has to be analysed following the corresponding EORTC manual http://www.eortc.be/qol/files/SCManualQLQ-C15-PAL.pdf and the overall quality of life assessment is contained in 0 to 100 where a higher value represents a better state.
| score on a scale | Paclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD] | Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FD | Paclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kg |
|---|---|---|---|---|---|---|
| Pain | 5.6 ± 9.6 | 8.3 ± 11.8 | -13.3 ± 21.7 | 13.3 ± 13.9 | -4.2 ± 21.0 | 12.5 ± 30.5 |
| Dyspnea | 0.0 ± 0.0 | 0.0 ± 47.1 | -6.7 ± 27.9 | 6.7 ± 14.9 | 11.1 ± 25.4 | 12.5 ± 24.8 |
| Insomnia | 0.0 ± 33.3 | 16.7 ± 23.6 | 0.0 ± 0.0 | -6.7 ± 14.9 | 4.2 ± 34.5 | -12.5 ± 30.5 |
| Appetite loss | -22.2 ± 38.5 | 0.0 ± 0.0 | -6.7 ± 14.9 | 0.0 ± 0.0 | 1.4 ± 30.3 | 16.7 ± 25.2 |
| Constipation | 11.1 ± 19.2 | 0.0 ± 0.0 | 6.7 ± 14.9 | 13.3 ± 29.8 | -2.8 ± 23.9 | 8.3 ± 23.6 |
| Overall QoL | 5.6 ± 9.6 | -16.7 ± 0.0 | -8.3 ± 21.5 | -6.7 ± 19.0 | -6.3 ± 22.4 | -10.4 ± 17.7 |
| Physical functioning | -11.1 ± 19.2 | -6.7 ± 9.4 | -2.7 ± 6.0 | -13.3 ± 8.2 | -2.8 ± 19.8 | -8.3 ± 17.0 |
| Fatigue | 3.7 ± 33.9 | 0.0 ± 0.0 | -2.2 ± 24.1 | 11.1 ± 13.6 | 6.5 ± 23.4 | 2.8 ± 22.0 |
| Nausea / vomiting | -5.6 ± 9.6 | 8.3 ± 11.8 | 0.0 ± 11.8 | 3.3 ± 7.5 | 3.5 ± 9.8 | 2.4 ± 6.3 |
| Emotional functioning | 16.7 ± 28.9 | -8.3 ± 35.4 | 0.0 ± 11.8 | 5.0 ± 33.1 | 6.3 ± 18.4 | 5.2 ± 16.0 |
Collected over Through study completion, an average of 5 cycles for PM1183 in cohort A and 9.5 cycles in cohort B were observed (1 cycle =3 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Paclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD] | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD] | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FD | 0/6 (0%) | 3/6 (50%) | 6/6 (100%) |
| Paclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD] | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] | 3/37 (8.1%) | 15/37 (40.5%) | 36/37 (97.3%) |
| Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kg | 2/14 (14.3%) | 7/14 (50%) | 12/14 (85.7%) |
| Event | Paclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD] | Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FD | Paclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kg |
|---|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 0/3 | 0/3 | 2/6 | 1/6 | 1/37 | 2/14 |
| Intestinal obstructionGastrointestinal disorders | 0/3 | 0/3 | 2/6 | 0/6 | 0/37 | 1/14 |
| PyrexiaGeneral disorders | 0/3 | 0/3 | 0/6 | 1/6 | 1/37 | 0/14 |
| NeutropeniaBlood and lymphatic system disorders | 0/3 | 0/3 | 1/6 | 0/6 | 1/37 | 0/14 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 0/6 | 0/6 | 0/37 | 2/14 |
| Chest painGeneral disorders | 0/3 | 0/3 | 0/6 | 0/6 | 0/37 | 1/14 |
| Large intestine perforationGastrointestinal disorders | 0/3 | 0/3 | 0/6 | 0/6 | 0/37 | 1/14 |
| Gallbladder obstructionHepatobiliary disorders | 0/3 | 0/3 | 0/6 | 0/6 | 0/37 | 1/14 |
| Back painMusculoskeletal and connective tissue disorders | 0/3 | 0/3 | 0/6 | 0/6 | 0/37 | 1/14 |
| Abdominal abscessInfections and infestations | 0/3 | 0/3 | 0/6 | 0/6 | 0/37 | 1/14 |
| Event | Paclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD] | Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FD | Paclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kg |
|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 2/3 | 3/3 | 6/6 | 6/6 | 27/37 | 10/14 |
| NeutropeniaBlood and lymphatic system disorders | 0/3 | 1/3 | 4/6 | 5/6 | 10/37 | 3/14 |
| AlopeciaSkin and subcutaneous tissue disorders | 1/3 | 1/3 | 1/6 | 5/6 | 9/37 | 5/14 |
| PyrexiaGeneral disorders | 0/3 | 2/3 | 1/6 | 2/6 | 7/37 | 0/14 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/3 | 1/3 | 4/6 | 2/6 | 11/37 | 3/14 |
| DiarrhoeaGastrointestinal disorders | 2/3 | 2/3 | 2/6 | 2/6 | 13/37 | 5/14 |
| NauseaGastrointestinal disorders | 2/3 | 2/3 | 2/6 | 4/6 | 24/37 | 6/14 |
| VomitingGastrointestinal disorders | 1/3 | 1/3 | 2/6 | 3/6 | 19/37 | 3/14 |
| Oedema peripheralGeneral disorders | 0/3 | 0/3 | 0/6 | 3/6 | 4/37 | 1/14 |
| AnaemiaBlood and lymphatic system disorders | 1/3 | 0/3 | 3/6 | 1/6 | 7/37 | 3/14 |
| Age, Categorical(Participants) | Paclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD] | Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FD | Paclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kg | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 3 | 6 | 5 | 23 | 12 | 51 |
| >=65 years | 1 | 0 | 0 | 1 | 14 | 2 | 18 |
| Age, Continuous(years) | Paclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD] | Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FD | Paclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kg | Total |
|---|---|---|---|---|---|---|---|
| Median | 57 (53 to 72) | 50 (31 to 55) | 53.5 (41 to 63) | 46.5 (38 to 68) | 61.0 (38 to 74) | 57 (47 to 72) | 57 (31 to 74) |
| Sex: Female, Male(Participants) | Paclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD] | Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FD | Paclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kg | Total |
|---|---|---|---|---|---|---|---|
| Female | 2 | 3 | 4 | 5 | 26 | 8 | 48 |
| Male | 1 | 0 | 2 | 1 | 11 | 6 | 21 |
| Region of Enrollment(Participants) | Paclitaxel [60.0 mg/m2] / PM01183 [3.0 mg FD] | Paclitaxel [60.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel 60.0 mg/m2 / PM01183 5.0 mg FD | Paclitaxel [80.0 mg/m2] / PM01183 [5.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] | Paclitaxel [80.0 mg/m2] / PM01183 [4.0 mg FD] / BEV 15 mg/kg | Total |
|---|---|---|---|---|---|---|---|
| Switzerland | 1 | 2 | 1 | 1 | 6 | 1 | 12 |
| Spain | 2 | 1 | 3 | 4 | 12 | 6 | 28 |
| United States | 0 | 0 | 2 | 1 | 19 | 7 | 29 |
The record gives a start of Sep 2013, a primary completion of Jul 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2020, 3 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: PM 01183 · Paclitaxel · Bevacizumab